We hope that the promising data regarding the beneficial effects of GLP-1 and dual GLP-1/GIP receptor agonists on EAT volume and function will not only be confirmed but also complemented in future clinical trials, providing further insight into their impact on the course and prognosis of obesity-related cardiomyopathy. The gene discussed is GLP1R; the disease is cardiomyopathy.